Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer

被引:10
|
作者
Hamada, Riu [1 ]
Nakashima, Jun [1 ]
Ohori, Makoto [1 ]
Ohno, Yoshio [1 ]
Komori, Osamu [2 ]
Yoshioka, Kunihiro [1 ]
Tachibana, Masaaki [1 ]
机构
[1] Tokyo Med Univ, Tokyo Med Univ Hosp, Dept Urol, Shinjuku Ku, 6-7-2 Nishi Shinjyuku, Tokyo 1608582, Japan
[2] Inst Stat Math, Dept Math Anal & Stat Inference, Tokyo, Japan
关键词
Radical prostatectomy; High-risk prostate cancer; PSA density; PSA density of the transition zone; Percentage of positive cores from the dominant side; Biochemical recurrence; BEAM RADIATION-THERAPY; RADICAL PROSTATECTOMY; DISEASE RECURRENCE; ANTIGEN DENSITY; FREE SURVIVAL; PERCENTAGE; CARCINOMA; FAILURE; BIOPSY; CORES;
D O I
10.1007/s10147-015-0923-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify preoperative predictive factors for biochemical recurrence (BCR) and to further stratify its risk in high-risk localized prostate cancer patients receiving radical prostatectomy (RP). Subjects included 195 high-risk prostate cancer patients undergoing RP from 2000 to 2012. RP consisted of retropubic radical prostatectomy and robot-assisted radical prostatectomy, involving 84 cases and 111 cases, respectively. BCR was defined as a prostate serum antigen (PSA) level a parts per thousand yen0.2 ng/mL. BCR-free survival (BCRFS) was calculated using the Kaplan-Meier method. Preoperative predictors of BCR were assessed with Cox's proportional hazard regression analysis. Eighty-nine patients (45.6 %) experienced recurrence. BCRFS rates 3 and 5 years after RP were 58 and 50 %, respectively. Prostate volume, transition zone volume, and Gleason score were not significantly associated with BCR. Patients with higher preoperative PSA, PSA density (PSAD), PSA density of the transition zone, percentage of positive cores (PPC), and PPC from the dominant side showed significantly lower BCRFS. The PPC from the dominant side and PSAD were significant independent prognostic factors for BCR. Using these variables, the hazard ratio of BCR could be calculated and patients stratified into three risk groups. The 5-year BCRFS rates for Groups 1, 2, and 3 were 64.9 %, 48.1 %, and 21.3 %, respectively. Patients with high-risk localized prostate cancer as currently defined do not have uniformly poor prognosis after RP. PPC from the dominant side and PSAD are significant predictors of BCR. These factors can identify high-risk patients with very poor prognosis.
引用
收藏
页码:595 / 600
页数:6
相关论文
共 50 条
  • [41] Surgical management of high-risk, localized prostate cancer
    Wilkins, Lamont J.
    Tosoian, Jeffrey J.
    Sundi, Debasish
    Ross, Ashley E.
    Grimberg, Dominic
    Klein, Eric A.
    Chapin, Brian F.
    Nyame, Yaw A.
    NATURE REVIEWS UROLOGY, 2020, 17 (12) : 679 - 690
  • [42] Localized intermediate- to high-risk prostate cancer
    Tritschler, S.
    Ganswindt, U.
    Stief, C. G.
    UROLOGE, 2016, 55 (03): : 318 - +
  • [43] Contemporary management of high-risk localized prostate cancer
    Garzotto M.
    Hung A.Y.
    Current Urology Reports, 2010, 11 (3) : 159 - 164
  • [44] Role of surgery in high-risk localized prostate cancer
    Lawrentschuk, N.
    Trottier, G.
    Kuk, C.
    Zlotta, A. R.
    CURRENT ONCOLOGY, 2010, 17 : S25 - S32
  • [45] Optimizing the Management of High-Risk, Localized Prostate Cancer
    Sundi, Debasish
    Jeong, Byong Chang
    Lee, Seung Bae
    Han, Misop
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (12) : 815 - 820
  • [46] Systemic treatments for high-risk localized prostate cancer
    Pignot, Geraldine
    Maillet, Denis
    Gross, Emmanuel
    Barthelemy, Philippe
    Beauval, Jean-Baptiste
    Constans-Schlurmann, Friederike
    Loriot, Yohann
    Ploussard, Guillaume
    Sargos, Paul
    Timsit, Marc-Olivier
    Vincendeau, Sebastien
    Pasticier, Gilles
    Borchiellini, Delphine
    NATURE REVIEWS UROLOGY, 2018, 15 (08) : 498 - 510
  • [47] High-risk localized prostate cancer: Integrating chemotherapy
    Oh, WK
    ONCOLOGIST, 2005, 10 : 18 - 22
  • [48] Surgical management of high-risk, localized prostate cancer
    Lamont J. Wilkins
    Jeffrey J. Tosoian
    Debasish Sundi
    Ashley E. Ross
    Dominic Grimberg
    Eric A. Klein
    Brian F. Chapin
    Yaw A. Nyame
    Nature Reviews Urology, 2020, 17 : 679 - 690
  • [49] Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y. Yu
    William K. Oh
    Current Oncology Reports, 2003, 5 (3) : 250 - 257
  • [50] Systemic treatments for high-risk localized prostate cancer
    Géraldine Pignot
    Denis Maillet
    Emmanuel Gross
    Philippe Barthelemy
    Jean-Baptiste Beauval
    Friederike Constans-Schlurmann
    Yohann Loriot
    Guillaume Ploussard
    Paul Sargos
    Marc-Olivier Timsit
    Sébastien Vincendeau
    Gilles Pasticier
    Delphine Borchiellini
    Nature Reviews Urology, 2018, 15 : 498 - 510